Comparative Pharmacology
Head-to-head clinical analysis: ALDACTONE versus TRIAMTERENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDACTONE versus TRIAMTERENE.
ALDACTONE vs TRIAMTERENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive aldosterone receptor antagonist; increases sodium and water excretion, decreases potassium excretion at distal convoluted tubule.
Triamterene is a potassium-sparing diuretic that inhibits epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct of the nephron, reducing sodium reabsorption and potassium excretion.
Initial: 50-100 mg orally once daily; may increase to 100-400 mg/day in divided doses (once to twice daily).
100-300 mg orally once daily; maximum 300 mg/day.
None Documented
None Documented
Spironolactone: 1.4-2.0 hours; Active metabolites (canrenone): 16.5-21.5 hours, clinically relevant for dosing interval
Clinical Note
moderateTriamterene + Digoxin
"The therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Digitoxin
"The therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Deslanoside
"The therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Acetyldigitoxin
Terminal elimination half-life is approximately 1.5 to 2 hours. However, in patients with hepatic cirrhosis, half-life may be prolonged up to 4 hours; in renal impairment, half-life can extend significantly (up to 10 hours) due to reduced renal clearance.
Renal: 50-60% as metabolites (canrenone, other sulfur-containing metabolites), minor as unchanged drug; Biliary/Fecal: ~30-40%
Approximately 50% of an oral dose is excreted unchanged in urine; about 20% is excreted as metabolites (mainly hydroxytriamterene sulfate conjugate) in urine; biliary/fecal excretion accounts for less than 10%.
Category C
Category A/B
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic
"The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene."